Newsroom

Obama’s Budget Targets High Cost of Cutting-Edge Drugs

With patients facing more exposure to the cost of revolutionary new medications, the budget President Barack Obama released Monday reopened a debate on whether government should use its buying power to squeeze the pharmaceutical industry for lower prices.

Read more

Abbvie Expects $3B In Hepatitis C Drug Sales And 40% Of Insured Customers

Abbvie, the maker of one of the costly hepatitis C pills captivating Wall Street and frustrating those who pick up the tab for health care costs, says its sales of its treatment will generate more than $3 billion in annual sales in 2015.

Read more

Harvard Pilgrim secures discount on Gilead’s newest hep C drug

Harvard Pilgrim Health Care, one of the largest not-for-profit health insurers in New England, said it will save millions of dollars in hepatitis C drug costs through its negotiated pricing discount from pharmaceutical giant Gilead.

Read more

Want To Control Drug Prices? Reject Price Controls

The past year has seen an epic confrontation pitting insurers and payers against drug companies.

Read more